Class actions accusing Forest Labs of illegally marketing anti-depressants for pediatric use have been consolidated as a multi-district litigation in the U.S. District Court for the District of Massachusetts in Boston. The suits accuse Forest of engaging in false and misleading promotion of Celexa and Lexapro for pediatric and adolescent use. It’s alleged in the complaints that the company promoted the results of a positive study on pediatric use of Celexa, while covering up negative results of another study.
It appears that the company encouraged doctors to increase prescriptions by giving them illegal payments, expensive meals and lavish entertainment. Two class actions were transferred to the MDL. One was originally filed in Missouri and one in New York. Three other cases had been filed in the MDL.
The cases include consumers and third-party payers who are seeking reimbursement for paying costs associated with the off-label promotion to children. In August, the Judicial Panel on Multidistrict Litigation ruled that Massachusetts is an appropriate forum for the litigation. This was because two qui tam actions were already pending there.
Source: Lawyers USA Online
Contact us today for a free legal consultation with an experienced attorney.
Fields marked *may be required for submission.
If you would like to subscribe to the Jere Beasley Report digital edition, simply visit our Subscriptions page and provide the necessary information or call us at 800-898-2034.
Attorney Advertising - Prior results do not guarantee a similar outcome.